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Introduction
MDMA, known scientifically as 3, 4-methylenedioxymetham-
phetamine, is an amphetamine derivative drug increasing in 
popularity amongst teenagers and young adults (Broening, et al., 
2001). Amphetamines are a class of molecules that have stimu-
lating effects on the central nervous system (CNS). MDMA is 
known by recreational users as ‘Ecstasy’ because it has stimu-
lating and hallucinogenic effects on the CNS while engender-
ing immediate feelings of ecstasy and openness upon ingestion 
(Singer, et al., 2012). 
Studies show that adults taking MDMA have a decrease in sero-
tonin (5-HT) in the brain, a reduction in 5-hydroxyindoleacetic 
acid (5-HIAA), a main metabolite of serotonin, and a reduction 
in tryptophan hydroxylase (TPH), an enzyme involved in the 
synthesis of serotonin (Broening, et al., 2001). This serotonergic 
reduction is harmful to the exposed adult. Interestingly, though 
the effects of MDMA on adults have been well researched, few 
studies have been conducted on the effects of MDMA on pre-
natally exposed children and on the reasons for these effects. 
Due to its popularity amongst teenagers and young adults, it 
has become increasingly prevalent to find developing fetuses 
exposed to MDMA while in utero. Scientists are determining 
the long term neurological effects of Ecstasy-exposed fetuses by 
conducting post parturition studies on both rats and children 
that have been prenatally exposed to MDMA. Some long term 
neurotoxic effects include sequential and spatial learning delays 
(Broening, et al., 2001) milestone delays at 4 months of age, and 
poorer mental development index scorings at 12 months of age 
(Singer, et al., 2012). The question stands as to why these and 
other neurotoxic effects develop  in both rats and children that 
have been exposed to MDMA in utero. Scientists are hypoth-
esizing numerous reasons for these effects, including serotonin 
(5-HT) reduction (Broening, et al., 2001), elevated levels of cor-
tisol (Parrott, et al., 2014), changes in the norepinephrine (NE) 
system (Thompson, et al., 2011) and in the dopamine (DA) sys-
tem (Thompson, et al., 2009), an increase in autophagy protein 
5 (Atg5) (Chae, et al., 2009), and embryotoxicity due to MDMA 
metabolites (Barenys, et al., 2012). This paper explores various 
venues theorized to be the cause of the cognitive and neuronal 
impairment observed in Ecstasy-exposed fetuses.
Methods
Research on the topic of the biological reasons for the neuro-
toxic effects of MDMA on the developing fetus was compiled 
from various sources found in the Touro database. Information 
was obtained regarding general usage of MDMA as well as 
the observations noted in children of women who ingested 
MDMA while pregnant. Finally, data about various experiments 
performed on rats was obtained in order to gain insight into 
possible biological causes for the neurotoxic deficits noted in 
MDMA exposed fetuses. The information was arranged into a 
comprehensive order and edited by the author.
Discussion
One strong hypothesis as to how Ecstasy induces long term 
brain damage in a fetus is that MDMA-exposed fetuses are 
harmed due to a decrease in 5-HT in the brain. This hypothesis 
is based on the established fact that MDMA causes serotonergic 
reductions in the adult brain. In a study done on Sprague-Dawley 
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rats, researchers in the University Of Cincinnati College Of 
Medicine sought to determine whether the effects of MDMA 
on exposed fetuses are indeed caused by a 5-HT reduction. 
Sprague Dawley rats were mated and their litters were reduced 
to 8 pups, 4 males and 4 females, with parturition day termed P0. 
The rats were divided into 2 groups. One group received two 
subcutaneous injections of MDMA daily on P1-P10 while the 
second group received similar MDMA injections on P11-P20. 
These intervals of P1-P10 and P11-P20 correspond to early and 
late third trimester development in humans, respectively. 
Between P60 and P80, the rats were tested in various assigns. 
The results of the tests illustrated that the rats in the P11-P20 
group had significant decreases in sequential learning, spatial 
learning, and memory abilities, while those in the P1-P10 group 
did not show significant decreases in any of these areas. Neither 
group showed a significant decrease in cued learning. These 
tests demonstrate that the neurotoxic effects that MDMA has 
on a developing fetus are more likely to occur when MDMA is 
taken during late third trimester development and that these 
effects are long term, as seen from the presence of the impair-
ments in rats that had already reached adulthood.
The researchers sought to determine whether these cognitive 
impairments in the rats were due to serotonergic decreases 
in the rat brains. In order to investigate this hypothesis, the 
rats were decapitated on P105 and their brains were dissected. 
Reductions in 5-HT in the hippocampus were found for both 
the P1-P10 and P11-P20 groups, findings that do not correlate 
with the cognitive impairments seen only in the P11-P20 groups. 
In addition, the frontal cortex of the rats displayed 5-HT reduc-
tions only in the P11-P20 group, but these reductions were in-
significant as seen with a correlation coefficient between these 
reductions and the spatial learning deficits exhibited by the rats 
that did not approach significance. Therefore, while this study 
shows that MDMA has long term negative effects on spatial 
and sequential learning and memory, it also illustrates that these 
cognitive deficits are not due to serotonergic reductions. The 
cause of fetal brain damage by MDMA must be via a mechanism 
other than the 5-HT reduction that causes MDMA induced 
damage in the adult brain (Broening, et al., 2001).
This idea that prenatal MDMA exposure and the long term 
damage that it causes is not due to 5-HT reduction can be sup-
ported by the mechanism via which MDMA causes 5-HT reduc-
tion in the adult brain. Studies indicate that MDMA metabolites 
form free radicals upon further metabolism and thereby dam-
age serotonergic neurons. This is supported by the presence 
of malondialdehyde in rat brains after exposure to MDMA. 
Malondialdehyde is an end product of lipid peroxidation, the 
process during which lipids in cell membranes are broken down 
via free radicals. Because free radicals are hard to measure due 
to their short half-lives, the by-products of these radicals known 
as TBARS (thiobarbituric acid reacting substances) are used to 
measure the damage induced by the free radicals. The TBARS 
Assay is a test that reacts thiobarbituric acid with malondial-
dehyde in order to quantify the amount of free radicals found 
in a specimen. This reaction yields a florescent product that 
indicates the presence of free radicals. Thus, a high yield of 
malondialdehyde from a TBARS Assay found in adult rats ex-
posed to MDMA indicates the presence of free radicals in these 
rats. Another indication of the presence of free radicals in rats 
exposed to MDMA is that 5-HT reduction is prevented from 
occurring in MDMA-exposed rats that are injected with alpha-
phenyl-N-tert-butyl nitrone (PBN), a free radical scavenger. This 
indicates that the 5-HT reduction occurring in adult rats may 
be happening in part because of free radicals. A study exposing 
both neonate and adult rats to MDMA showed no significant 
increase in the presence of malondialdehyde in the hippocam-
pus and cortex of the neonate rats while the adults’ brain cor-
tices did demonstrate a significant increase in malondialdehyde 
(Figure 1). Free radicals cause the serotonergic reduction in 
adult rats, and it can be inferred that cognitive defects found 
in adult humans exposed to MDMA are caused by this 5-HT 
reduction. In contrast, neonatal rats and, by inference, humans 
prenatally exposed to MDMA, have cognitive impairments that 
cannot be attributed to 5-HT reductions (Colado, et al., 1997). 
Other factors must be explored to lend reason for these long 
term neurotoxic effects.
Another possible cause for the cognitive deficits recognized 
in children prenatally exposed to MDMA is elevated levels of 
Figure 1 - Formation of thiobarbituric acid reacting substances 
(TBARS) in the hippocampus and cortex of adult rats and cortex of 
neonate rats 3 h (hatched columns) and 6 h (cross-hatched columns) 
after MDMA (40 mg kg71, i.p.) administration. Results show % 
change in brain malondialdehyde (MDA) formation compared to 
saline-injected control animals (open columns), as mean+s.e.mean, 
n=8± 10. *Significantly different from saline (Colado, et al., 1997).
Figure 1
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cortisol caused by ingestion of Ecstasy. As noted, MDMA has 
been shown to cause impairments in long term memory, learn-
ing, and locomotor activity in children exposed to this drug in 
utero. Researchers hypothesize that these impairments may be 
due to the increase in cortisol that is present. Individuals in-
gesting Ecstasy display higher levels of cortisol in comparison 
to drug-free individuals with baseline cortisol levels. In addition, 
increased cortisol levels may be damaging to fetal development. 
Therefore, if the Ecstasy user is a pregnant woman, her MDMA 
usage may put her fetus at risk (Parrott, et al., 2014).
Cortisol is a glucocorticoid steroid hormone produced by the 
adrenal cortex in response to bodily stress and/or low blood 
glucose levels. The body releases this hormone in order to pro-
vide additional metabolic resources that enable an individual to 
function properly while under stress. The hypothalamic- pitu-
itary-adrenal (HPA) axis is a systemic interaction of endocrine 
glands that utilize a negative feedback mechanism in order to 
control the hormonal activities of the adrenal cortices (Mosby’s 
Medical Dictionary, 2009). 
In a recent study performed on MDMA users, light usage of 
MDMA (ingestion of MDMA 1-4 times within the past 3 
months) led to a mean increase of 50% in cortisol levels, in con-
trast with a control group of MDMA-free individuals. Heavier 
Ecstasy users (ingestion of MDMA 5+ times within the past 3 
months) were noted to have a mean increase of 400% in their 
cortisol levels in comparison with a control group. While these 
statistics definitely illustrate radical increases in cortisol levels 
in MDMA users, a 10% increase of maternal cortisol leads to a 
mere 1% increase in fetal cortisol. This is due to the placental 
glucocorticoid barrier that prevents most of the cortisol from 
reaching the fetus. However, while a small increase in maternal 
cortisol levels may not cause damage to a fetus, a 400% increase 
in maternal cortisol can possibly have long term deleterious ef-
fects on the child. 
According to the scientific review by Parrott, et al.(2014), “…
HPA basal hyperactivation…may represent a complex neuro-
endocrine dysfunction associated with MDMA use.” They imply 
that elevated cortisol levels caused by MDMA ingestion may 
lead to HPA axis impairments, specifically in a developing fetus. 
This idea is supported by a study on the effects of maternal 
stress on a fetus, because researchers have found that similar 
to ingestion of MDMA, an increase in a mother’s stress level 
causes more cortisol to be produced, and this hormone is then 
passed to the fetus via the placenta. As noted, although most 
of the cortisol is prevented from reaching the fetus due to the 
placental glucocorticoid barrier, about 1/10th of the cortisol 
will still reach the fetus. This hormone may then reprogram the 
HPA axis activity of the developing fetus which can cause long 
term damaging effects on the child. Studies illustrate that the 
negative effects of stress on the developing fetus include poorer 
attention spans, sleeping, feeding, and activity problems, great-
er impulsivity, and a higher pervasiveness of Attention Deficit 
Hyperactivity Disorder (ADHD). Because ingestion of MDMA 
causes an increase in cortisol in the same way that maternal 
stress does and because cortisol has been shown to cross the 
placental barrier, researchers infer that it is the elevated cortisol 
levels found in MDMA users that are responsible for the neu-
rotoxic deficits found in Ecstasy-exposed fetuses and that the 
long term effects of MDMA may mirror the effects of maternal 
stress on a fetus.
It is interesting to note that increased cortisol levels can be seen 
in an individual for up to 3 months after he/she has stopped 
using MDMA. Thus, it follows that a woman who stops MDMA 
usage prior to pregnancy may still be liable to inflict lasting 
damage to her fetus unless she has had several months of drug 
abstinence prior to conception (Parrott, et al., 2014).
A study researching the connection between elevated cortisol 
levels and memory problems supports the idea that elevated 
cortisol levels may be the cause of long term damage in MDMA-
exposed fetuses, specifically in the area of memory impairment. 
Researchers tested healthy individuals with a mean age of 61.8 
years to determine if memory problems are linked to elevated 
cortisol levels. This study used a special testing method in order 
to control for any stress that would develop in the subjects 
because of the inherent knowledge of their memory loss. The 
study demonstrated that women with memory complaints 
had significantly higher levels of cortisol than women without 
memory complaints, although no such difference was seen in 
men. In addition, individuals who complained of memory issues 
also had increased activity of their HPA axes (Wolf, et al., 2004). 
Similar to the adults in this study, fetuses exposed to MDMA 
also had elevated cortisol levels and hyperactivity of their HPA 
axes (Parrott, et al., 2014). In a similar vein, a study performed 
on cocaine dependent individuals served to analyze the cause 
for the learning and memory dysfunctions observed in these 
drug addicts. Researchers determined that cocaine dependent 
individuals have higher levels of cortisol than individuals in a 
‘cocaine-free’ control group, and this increase was associated 
with the poorer learning and memory skills observed in these 
individuals (Fox, et al., 2009).Thus, it can be inferred that the 
memory impairments noted in children prenatally exposed to 
MDMA may be caused by the elevated cortisol levels that these 
fetuses are exposed to.
Another hormone that may be linked to the damage induced 
by MDMA in the developing fetus is norepinephrine (NE). NE 
is a noradrenergic hormone and neurotransmitter made from 
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dopamine (DA) by the enzyme dopamine beta hydroxylase 
(DBH). It is released from the adrenal medulla into the blood-
stream and acts as a systemic hormone, and it is also released 
from noradrenergic neurons in the locus ceruleus of the brain 
where it acts as a neurotransmitter. Scientists have found that 
a correlation exists between prenatal exposure to MDMA in 
rats and changes in the structure and function of the NE sys-
tem in these prenatally exposed rats. NE system dysfunction 
has been associated with exaggerated behavioral responses to 
new stimuli as well as a decrease in habituation to these stim-
uli, impairments which are attributed to attentional processing 
deficits. Because researchers have observed these behaviors in 
prenatally exposed rats, they  infer that the damage induced by 
MDMA exposure to a developing fetus may be linked to abnor-
mal wiring of the fetus’s NE system (Thompson, et al., 2011).
In order to test this hypothesis, pregnant Sprague-Dawley rats 
were randomly assigned to two groups. One group was injected 
with 15mg/kg of MDMA twice a day at 8 hour intervals, a dose 
consistent with the typical MDMA dosage taken for human 
consumption, while the other group received subcutaneous 
injections of saline two times a day at corresponding 8 hour 
intervals. These injections were administered from embryonic 
day 14 (E14) to embryonic day 21 (E21). The pups were born on 
E21 and the first day after parturition was termed postnatal day 
1 (P1). The litters were reduced to 4 males and 4 females for the 
MDMA group and 5 males and 5 females for the saline group. 
The pups were anesthetized on P21 and their brains were re-
moved and cut into specific sections for observational analysis.
Among the different areas of the brain that were analyzed, three 
sections of the rostral hippocampus, CA1, CA2, and CA3, were 
scrutinized for NE abnormalities. This section of the brain was 
studied because it is receives noradrenergic innervation from 
the locus ceruleus and because it is involved in spatial memory 
and responses to novelty, abilities that have been found lack-
ing in MDMA exposed fetuses. The rats prenatally exposed to 
MDMA exhibited a 32.1% increase in DBH fiber density in the 
CA1 region of the hippocampus in comparison with the control 
group. In addition, norepinephrine transporter (NET), a mole-
cule that regulates NE signaling by clearing NE from the synaptic 
cleft, increased in MDMA rats by 39.3% in the CA1 region and 
32.1% in the CA3 region. In spite of these increases, the rostral 
hippocampus displayed no elevation in NE levels and levels of 
3-methoxy-4-hydroxyphenolglycol (MHPG), a main metabolite 
of NE. The locus ceruleus displayed no increase in DBH fibers, 
and NET binding did not increase in this area. However, in the 
prelimbic (Cg3) region of the prefrontal cortex, there was a 
69.2% increase in DBH neurites. This was accompanied by a 
15% increase in NE in the prefrontal cortex as a whole, although 
there was no increase in NET binding or MHPG levels in the 
prefrontal cortex.
These findings suggest that MDMA can cause NE system dys-
function in the developing fetus. As an example, the increase 
in NET binding observed in the CA1 and CA3 regions of the 
hippocampus illustrate that MDMA caused more NE to con-
tinue to be present in these areas even after exposure, or that 
the high levels of NE found in the hippocampus during MDMA 
exposure led to a sustained increase in NET binding in these 
areas as a form of systemic regulation. Because NE in the CA1 
region of the hippocampus plays a big role in communication 
signaling between the hippocampus and entorhinal cortex, NE 
abnormalities in this region may lead to communication deficits 
which in turn may lead to impairments in spatial learning and 
working memory. In fact, as illustrated in other studies pre-
viously mentioned, these deficits have been found in rats ex-
posed to MDMA while in utero. Also, as mentioned previously, 
NE increases have been related to exaggerated responses to 
novelty and attentional processing impairments. These deficits 
also correlate with a study that observed that rats exposed to 
MDMA while in utero had increased levels of responsivity to a 
new cage at P21, an increase that persisted into adulthood as 
far as P61-P62. Therefore, it can be theorized that NE system 
changes caused by rat embryonic exposure to MDMA, and, by 
inference, NE system changes caused by human fetal exposure 
to MDMA, lead to many of the impairments observed in chil-
dren prenatally exposed to MDMA. Changes in the noradren-
ergic system that develop in the fetus as a result of MDMA ex-
posure have direct links to the deficits noted in these children 
post-parturition. 
It is worth mentioning that the results of the MDMA exposure 
are noted on P21, and that this corresponds to the early teen-
age years in humans. Thus, NE system changes and the resulting 
impairments can be effective in this time period. These system-
ic deficits may be the cause of the impulsivity and ‘search for 
novelty’ that is present amongst many young adults that often 
leads to substance abuse or reckless behavior (Thompson, et 
al., 2011). Perhaps the mothers ingesting MDMA while preg-
nant are unknowingly setting the stage for substance abuse in 
their children many years down the line.
In a similar study, scientists determined that fetal rat exposure 
to MDMA affects the fetus’s dopamine (DA) system. These ef-
fects can be seen by a five-fold increase in dopamine neuron 
fibers in the prefrontal cortex of the rat brain as well as by 
smaller increases in DA fiber density in the striatum and nu-
cleus accumbens of rats exposed to MDMA while in utero. 
DA has many pathways in the brain, one of which is the meso-
cortical tract, a pathway that transports DA from the ventral 
tegmentum to the frontal cortex. The pathway is known to 
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influence exploratory behaviors, impulsivity, and a search for 
novelty. When this system is impaired, the results can cause hy-
peractivity and are sometimes linked to behavioral issues such 
as ADHD. Because changes in the DA system of both humans 
and rats is associated with decreased habituation to novelty 
and increased locomotor activity, this study sought to discover 
whether the changes in the DA system noted in the rats ex-
posed to MDMA could be correlated with significant changes 
in these particular behavioral areas (Thompson, et al., 2010). 
The study tested Sprague Dawley rats that were injected with 
MDMA on embryonic day 14-20, as well as a group of ‘control’ 
rats, and measured their behavior on postnatal day 21. Many 
behavioral areas such as home cage locomotor activity, running 
wheel activity, gravitation towards a high fat diet, and cocaine 
self-administration levels where tested. However, the only areas 
of behavior that had significant results in comparison with the 
control group were the rats’ decreased acclimation to new 
environments, increased perseverance to find a cued platform, 
and increased locomotion in the center of an open field which 
served as an indication of the rats’ decreased levels of anxi-
ety. Thus, the researchers hypothesized that the rats exposed 
to MDMA in utero had alterations in their dopamine systems, 
specifically in the mesocortical pathway. They conjectured that 
a possible cause for the decreased habituation to novelty and 
increased perseverance seen in the rats was caused by impair-
ments that the MDMA wreaked on the fetal rats’ developing 
DA systems (Thompson, et al., 2010).
Another study researching deficits found in fetuses exposed 
to MDMA explores impairments in neuronal differentiation 
that arise due to an increase in an autophagy-related protein 
5 (Atg5). Autophagy is an intracellular process that involves 
packaging unneeded cytoplasm and organelles into vesicles 
known as autophagosomes in preparation for degradation 
so that the cell can recycle these particles. After an isolation 
membrane elongates and surrounds unneeded cellular parti-
cles, an autophagosome is formed which fuses with a lysosome, 
eventually leading to the catalytic breakdown of the extraneous 
cellular particles. Seven proteins known as autophagy-related 
proteins regulate this process. These proteins are grouped into 
two distinct categories – the Atg12 system (comprised of Atg 
5, 7, 10, and 12) which involves regulating the elongation of 
the autophagosome isolation membrane, and the Atg8 system 
(comprised of Atg 3,4,7, and 8), a system involved in regulating 
the attachment of the phospholipids in the autophagosome 
membrane (Chae, et al., 2009). 
Defects in the autophagy system have been linked to various 
physiological impairments. In this study, researchers discovered 
that rats embryos injected with MDMA had elevated levels of 
Atg5. The study explanted rat embryos after 8.5 days of gestation 
and administered dos es of 2.5, 5, and 10 micrograms of MDMA 
to the embryos. When the embryonic mRNA was sampled, it was 
noted that Atg5 expression had doubled after 48 hours of MDMA 
exposure and that extreme teratogenesis and fetal brain damage 
was observed in the rats (Figure 2). In order to determine if this 
brain damage occurred due to impairment of neuronal differen-
tiation, human neuroblastoma SH-SY5Y cells were divided into 
two groups, a control group and a group injected with 10 micro-
grams of MDMA. The group of cells administered with MDMA 
illustrated an increase of 1.8 times the amount of Atg5 mRNA 
expression after 48 hours. Furthermore, when a sample of SH-
SY5Y cells was induced with a green florescent protein vector 
(GFP), a protein used as a marker of genetic expression, in the 
presence of a plasmid encoding for Atg5, the cells did not express 
This diagram illustrates images of fetal brain development of various rat embryos that received specific doses of MDMA on gestational 
day 8.5. Note how the teratogenic effects pointed out by the arrows are in concordance with the higher dosages of MDMA (Chae, et 
al.,2009)
Figure 2
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any neurite extensions or arborizations (fine branching at the 
end of the neurite fiber). This was in the presence of retinoic 
acid, a metabolite of vitamin A that usually aids in growth and 
development. In contrast, a control group of SH-SY5Y cells in-
duced with a GFP vector and retinoic acid in the absence of Atg5 
exhibited extensive neurite extension and arborization (Figure 
3). This demonstrates that an increase in Atg5 impairs neuronal 
growth and differentiation. Therefore, because an increase in Atg5 
is found to impair the differentiation of SH-SY5Y neuroblastoma 
cells, it can be inferred that the teratogenesis observed in rats ex-
posed to MDMA that is accompanied by an increase in Atg5 can 
be attributed to a similar mechanism of impairment of neuronal 
differentiation (Chae, et al,. 2009).
An additional area that can be explored in order to explain the 
neuronal impairments discovered in fetuses exposed to MDMA 
is the metabolites that MDMA forms upon ingestion. As stat-
ed previously, when MDMA enters the body, it is broken down 
into substances that are further metabolized into free radicals. 
This is supported by the presence of malondialdehyde (MDA) 
in rat brains after exposure to MDMA, because MDA is one of 
the end products of lipid peroxidation, a process during which 
lipids in cell membranes are broken down via free radicals. 
However, MDMA forms other metabolites aside from MDA, 
depending on which enzymes are present to break it down. 
Therefore, while the formation of the MDA metabolite ac-
counts for the breakdown of 20-90% of MDMA ingested by rats, 
3, 4-Dihydroxymethamphetamine (HHMA) is a metabolite of 
MDMA that is formed upon human consumption and accounts 
for 53-81% of MDMA metabolism in humans. The difference in 
MDMA metabolism that results in the formation of MDA or 
HHMA is very slight. Ortho-demethylenation of MDMA, which 
occurs in humans, leads to the formation of HHMA, while 
N-demethylation, occurring in rats, leads to the formation of 
MDA (Figure 4). MDMA does metabolize into MDA in humans, 
as does MDMA metabolize into HHMA in rats, but only trace 
amounts of these metabolites are found in humans and rats, 
respectively (Barenys, et al., 2012). 
Researchers have found that the presence of HHMA or MDA 
while a fetus is developing can lead to embryonic defects in the 
fetus. Scientists explanted embryos from Sprague Dawley rats 
after 9.5 days of gestation and injected various embryos with 
MDMA, MDA, and HHMA. The concentrations of the injections 
for each substance were 5, 15, 25, and 50 micrograms. They 
discovered that the embryos injected with 25 and 50 micro-
grams of MDMA had a decrease in crown-rump length (CRL), a 
measurement of the fetus from the top of the head (crown) to 
the bottom of the buttocks (rump). In addition, abnormal tissue 
formations, known as dysmorphogeneses, were observed in the 
rats injected with 50 micrograms of MDMA. These dysmor-
phogeneses displayed themselves as an opening in the superior 
frontal tissue of the head, termed an open cranial neural pore, 
an abnormal prominence in the inferior frontal part of the head, 
termed a protuberant nasal placode, and a disproportionately 
small forebrain in comparison with the midbrain and hindbrain 
(Barenys, et al., 2012). 
Similarly, the embryos injected with doses of MDA displayed a 
decrease in their CRL after receiving a dose of 50 micrograms 
of MDA. These rats also exhibited dysmorphogeneses such as 
the posterior part of the embryonic trunk located behind the 
embryo instead of in front of it, termed an abnormal flexion, 
an abnormal caudal part of the embryo that was marked by a 
bend in the distal part of the embryo’s trunk, abnormally shaped 
somites, and unusual narrowing of the otic vesicles that repre-
sented the formation of irregular ears (Barenys, et al., 2012). 
The embryos injected with doses of HHMA also displayed 
This figure depicts the SH-SY5Y cells that were induced with GFP 
vector and retinoic acid for 5 days. The control group (top row) was 
imaged after 5 days while the test group (bottom row) was induced 
with Atg5 and also imaged after 5 days. Neurite extension and 
arborization is present and can be seen in the control group while no 
extension and arborization is present in the test group (Chae, et al., 
2009).
Figure 3
Figure 4 - This diagram illustrates the two main metabolic 
pathways of MDMA. O-demethylenation produces HHMA and is 
the main pathway that occurs in humans while N-demethylation 
produces MDA and is the main metabolic pathway that occurs in 
rats (Barenys, et al., 2012).
Figure 4
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similar anomalies. Interestingly, the group of embryos injected 
with 50 micrograms of HHMA died upon exposure to this 
concentration of metabolite. Therefore, the doses were mod-
ified to 10, 20, 30, and 40 micrograms of HHMA per group of 
embryos. At both 30 and 40 micrograms of HHMA, the CRL of 
the embryos significantly decreased. Additionally, dysmorpho-
geneses such as abnormal flexion, a protuberant nasal placode, 
and an abnormal yolk sac (an anomaly marked by a yolk sac that 
was not properly rounded or was missing vasculature) were 
noted in the embryos injected with 40 micrograms of HHMA 
(Barenys, et al., 2012). 
This research indicates that MDMA severely damages a de-
veloping fetus due to the toxic metabolites that are formed 
upon MDMA ingestion. However, it must be addressed why the 
dysmorphogeneses noted in the fetuses exposed to MDMA 
differed from those noted in the fetuses exposed to MDA 
and HHMA. While some of the abnormalities such as a pro-
tuberant nasal placode and decreased CRL were seen in both 
the MDMA-exposed embryos and the MDA and/or HHMA-
exposed embryos, there were anomalies noted in the MDA and 
HHMA-exposed embryos that were not found in the MDMA-
exposed embryos. This presents a problem, because MDA and 
HHMA are metabolites of MDMA and therefore, all of the 
anomalies found in an embryo exposed to these metabolites 
should be found in an embryo exposed to MDMA. Perhaps this 
can be explained by the fact that MDMA forms many metabo-
lites upon ingestion, aside from MDA and HHMA. It is possible 
that the ‘other’ metabolites of MDMA interact with one anoth-
er and ‘change’ the irregularities noted in embryos exposed to 
MDA or HHMA to represent those seen in embryos exposed 
to MDMA. 
Additionally, it is worth focusing on the fact that the HHMA 
killed the embryos that received injections of 50 micrograms 
while this did not occur to the embryos receiving injections 
of 50 micrograms of MDA. HHMA is the main metabolite of 
MDMA in humans, and this finding suggests that it is more toxic 
than MDA, the main metabolite of MDMA that is found in rats. 
Because many of the studies available today about MDMA and 
its harmful effects have used rats as their method of research, 
perhaps humans need to be extra cautious when ingesting 
MDMA. This is because the negative effects that MDMA has 
been shown to display in rats is probably greater in humans 
since HHMA is the main metabolite of MDMA in humans and 
appears to be a more toxic metabolite than MDA.
Conclusion
MDMA is an illicit, amphetamine derivative drug known as 
‘Ecstasy’ that causes harm to a developing fetus exposed to 
this drug while in utero. Scientists have confirmed that fetus-
es exposed to MDMA exhibit shorter attention spans, poorer 
memory, decreased habituation to novelty, poorer mental de-
velopment index scorings, and other neurological impairments. 
While researchers have determined the negative effects that 
MDMA has on a fetus, the biological reasons for these effects 
are still being researched extensively. Scientists have determined 
that these deficits are not due to 5-HT reductions in the brain. 
However, these defects may be caused by changes in the fetuses’ 
cortisol levels, systemic NE or DA changes that are caused by 
exposure to MDMA, an increase in Atg5 that leads to inhibi-
tion of neuronal growth and differentiation, or the embryotoxic 
effects of HHMA and MDA, two main metabolites of MDMA. 
These explanations require further research to determine how 
they interrelate with one another. Additional studies can inves-
tigate the interactions of all of the systemic changes caused by 
fetal exposure to MDMA to explore how these interactions 
bring about the cognitive deficits noted in MDMA-exposed 
fetuses. While this area of research has yet to be explored, indi-
viduals should take note that the harmful effects of MDMA have 
already been determined with certainty and that consumption 
of this drug should be avoided. 
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